Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul 6;2(3):1432-40.
doi: 10.3390/cancers2031432.

PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis

Maciej Salagierski  1 , Jack A Schalken
Affiliations

PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis

Maciej Salagierski et al. Cancers (Basel). .

Abstract

The search for the biomarkers to precisely and non-invasively characterize the biology of prostate cancer (PCa) is the focus of many laboratories across the world. Although prostate-specific antigen (PSA) remains the standard diagnostic tool for PCa, its low specificity leads to unnecessary biopsies in a substantial number of patients. More importantly, with the current status of knowledge, it is very difficult to early identify individuals with a life-threatening disease who require an immediate treatment. The significant advances in genetics and biotechnology in recent years has led to the discovery of new molecular markers including PCA3 and the TMPRSS2:ERG genomic fusion. Both PCA3 and TMPRSS2:ERG, compared to PSA, show an increased specificity in PCa detection. However, the quest for a single PCa marker that can fully satisfy urologists and their patients is still ongoing. The aim of this review is to present the recent findings on PCA3 and TMPRSS2:ERG and to describe their clinical implications and performance.

PubMed Disclaimer

References

    1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008;58:71–96. doi: 10.3322/CA.2007.0010. - DOI - PubMed
    1. Roobol M.J., Zappa M., Maattanen L., Ciatto S. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC) Prostate. 2007;67:439–446. doi: 10.1002/pros.20545. - DOI - PubMed
    1. Parekh D.J., Ankerst D.P., Troyer D., Srivastava S., Thompson I.M. Biomarkers for prostate cancer detection. J. Urol. 2007;178:2252–2259. doi: 10.1016/j.juro.2007.08.055. - DOI - PubMed
    1. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., Smit F.P., Karthaus H.F., Schalken J.A., Debruyne F.M., Ru N., Isaacs W.B. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59:5975–5979. - PubMed
    1. Clarke R.A., Zhao Z., Guo A.Y., Roper K., Teng L., Fang Z.M., Samaratunga H., Lavin M.F., Gardiner R.A. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS ONE. 2009;4:e4995. doi: 10.1371/journal.pone.0004995. - DOI - PMC - PubMed